Autologous Immunotherapy in Malaysia | Autologous Cell Therapy - Carerm
We are developing a 3D co-culture platform from the biopsy tissue of the cancer patient. We will screen various chemo regimes to provide the short-list of the most efficacious chemo regimes in two weeks. We will screen stand-alone drugs as well as various combinations of all chemo drugs identified as potentially useful by the oncologist treating the particular patient. This information would be extremely useful for the physician (especially in the context of the second-line therapy) as it helps reduce uncertainty in prescribing drug regimen that is most likely to be effective for that particular cancer patient. The current trial-and-error approach to identify the most effective cancer may lead to significant loss of time (4 to 5 months) during which the patient may continue to deteriorate.